COMMUNIQUÉS West-GlobeNewswire

Spectral AI Named to TIME’s List of World’s Top HealthTech Companies 2025
19/09/2025
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
19/09/2025
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children ( > 15 kg) living with severe allergic reactions Alfresa Holdings, which [...]
Jushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Parma in Ohio, Expanding its Statewide Retail Footprint
19/09/2025
Sixth Beyond Hello Location in Ohio and 41 st Retail Location Nationwide New Dispensary Opens September 19 th in Parma, Just South of Cleveland Grand Opening Celebration with Exclusive Promotions September 19 – October [...]
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
19/09/2025
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in [...]
NTA Implant: Solidifying Global Leadership with MDR Certification and Launching a New Era in Implantology
19/09/2025
EGOLZWIL, Switzerland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- NTA Implant, a leading brand of the Switzerland-based Pilatus Swiss Dental GmbH, has announced a strategic milestone in its global growth journey by successfully [...]
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
19/09/2025
Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the [...]
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
19/09/2025
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years 1 Subcutaneous Lunsumio has potential to substantially reduce [...]
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
19/09/2025
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
19/09/2025
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive CHMP [...]
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
19/09/2025
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical [...]
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
19/09/2025
GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply [...]
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
19/09/2025
Acquisition of leading cannabis company marks major milestone in InterCure’s commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as [...]
MomentMD Expands Virtual Clinical Education Platform Amid Growing Provider Shortages and Clinical Rotation Crisis
19/09/2025
With new partnerships and technology updates, the first-of-its-kind platform offers graduate programs immediate solutions to placement bottlenecks MomentMD Logo FORT LAUDERDALE, Fla., Sept. 19, 2025 (GLOBE NEWSWIRE) -- [...]
CrazyBulk 2025 | D-BAL, Testo-max , Trenorol , Ultimate Stack Legal Steroids Alternatives launch BY CrazyBulk In USA.
19/09/2025
CrazyBulk introduce safe and effective formula as best Legal Steroids Alternatives for muscle building and bodybuilding without any side effects over the counter supplement new york, Sept. 19, 2025 (GLOBE NEWSWIRE) -- [...]
Signature HealthCARE Committed to Proactive Resident Safety with SafeSpace Global Corporation
19/09/2025
Knoxville, TN, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to announce an expanded partnership with Signature HealthCARE. [...]
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share
19/09/2025
SAN JUAN CAPISTRANO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
19/09/2025
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye [...]
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
19/09/2025
Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavirus Supply is being [...]
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
19/09/2025
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive [...]

Pages